AR043660A1 - El tratamiento de la enfermedad de alzheimer - Google Patents

El tratamiento de la enfermedad de alzheimer

Info

Publication number
AR043660A1
AR043660A1 ARP040100921A ARP040100921A AR043660A1 AR 043660 A1 AR043660 A1 AR 043660A1 AR P040100921 A ARP040100921 A AR P040100921A AR P040100921 A ARP040100921 A AR P040100921A AR 043660 A1 AR043660 A1 AR 043660A1
Authority
AR
Argentina
Prior art keywords
disease
alzheimer
treatment
beta
ifn
Prior art date
Application number
ARP040100921A
Other languages
English (en)
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of AR043660A1 publication Critical patent/AR043660A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere al uso de interferón-beta (IFN-beta) para tratar y/o impedir la enfermedad de Alzheimer (AD), la enfermedad de Creutzfeld-Jakob (CJD) o la enfermedad de Gerstmann- Strrussler-Sceinker (GSSD). Además se refiere al uso de INF-beta en combinación con un agente para el tratamiento de la enfermedad de Alzheimer para el tratamiento y/o la prevención de la enfermedad de Alzheimer. Se prefiere el uso de IFN-beta en combinación con un inhibidor de la colinesterasa para el tratamiento y/o la prevención de la enfermedad de Alzheimer de comienzo precoz.
ARP040100921A 2003-03-19 2004-03-19 El tratamiento de la enfermedad de alzheimer AR043660A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03100716 2003-03-19

Publications (1)

Publication Number Publication Date
AR043660A1 true AR043660A1 (es) 2005-08-03

Family

ID=33016977

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100921A AR043660A1 (es) 2003-03-19 2004-03-19 El tratamiento de la enfermedad de alzheimer

Country Status (14)

Country Link
US (1) US20070110715A1 (es)
EP (1) EP1620124A2 (es)
JP (1) JP2006520368A (es)
KR (1) KR20050115279A (es)
CN (1) CN1791423A (es)
AR (1) AR043660A1 (es)
AU (1) AU2004222529A1 (es)
BR (1) BRPI0408491A (es)
CA (1) CA2516990A1 (es)
EA (1) EA009668B1 (es)
IL (1) IL170751A0 (es)
MX (1) MXPA05009986A (es)
NO (1) NO20054744L (es)
WO (1) WO2004082706A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060133008A (ko) * 2004-04-14 2006-12-22 워너-램버트 캄파니 엘엘씨 알츠하이머병을 치료하기 위한 치료용 조합물
US7695911B2 (en) * 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
CN101437510B (zh) * 2006-03-20 2012-12-05 科学与工业研究会 用作乙酰胆碱酯酶抑制剂的药物组合物
CN101116670B (zh) * 2006-08-01 2010-11-10 广州和竺生物科技有限公司 可提供活性甲基或参与甲基转移的化合物作为制备治疗病毒性疾病的药的应用
CA2661558A1 (en) * 2006-08-21 2008-02-28 Novartis Ag Biomarkers for alzheimer's disease progression
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2010056622A1 (en) * 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CN102382096A (zh) * 2011-09-06 2012-03-21 清华大学 异香豆素及其衍生物的制备方法
CN102707065A (zh) * 2012-03-23 2012-10-03 常熟市虞山绿茶有限公司 Prohibitin蛋白抗体在制备诊断老年性痴呆的试剂盒中的应用
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US9116974B2 (en) * 2013-03-15 2015-08-25 Robert Bosch Gmbh System and method for clustering data in input and output spaces
CN106754995B (zh) * 2016-11-25 2020-07-10 山东农业大学 中华蜜蜂AccCDK5基因及AccCDK5r1基因及其应用
RU2729391C2 (ru) * 2018-12-28 2020-08-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CN109518211B (zh) * 2019-01-08 2020-11-06 合肥工业大学 一种芳香偶酰类化合物的电化学合成方法
WO2023080687A1 (ko) * 2021-11-03 2023-05-11 가천대학교 산학협력단 아밀로이드 베타 멀티머 저해 약물의 고속 대량 스크리닝 방법 및 독소루비신 또는 이의 유도체를 포함하는 아밀로이드 베타의 올리고머화 또는 섬유화 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057879A1 (en) * 1999-03-26 2000-10-05 Barry Reisberg Treatment of brain changes with myelin protective agents
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system

Also Published As

Publication number Publication date
KR20050115279A (ko) 2005-12-07
NO20054744L (no) 2005-10-14
CA2516990A1 (en) 2004-09-30
CN1791423A (zh) 2006-06-21
BRPI0408491A (pt) 2006-04-04
JP2006520368A (ja) 2006-09-07
AU2004222529A1 (en) 2004-09-30
WO2004082706A3 (en) 2005-01-13
EA200501479A1 (ru) 2006-02-24
IL170751A0 (en) 2011-08-01
US20070110715A1 (en) 2007-05-17
MXPA05009986A (es) 2005-11-04
EP1620124A2 (en) 2006-02-01
WO2004082706A2 (en) 2004-09-30
EA009668B1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
GB0225474D0 (en) Therapeutic agents
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
GB0025173D0 (en) Therapeutic agents
GB0223040D0 (en) Therapeutic compounds
GB0225475D0 (en) Therapeutic agents
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
CY2014031I1 (el) Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
BR0211769A (pt) Combinações antineoplásicas
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG105575A (en) Method and agent for the treatment of cerebral ischaemia
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
MY137766A (en) Exemestane as chemopreventing agent
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
NL1025844A1 (nl) Benzopyranverbindingen voor gebruik bij de behandeling en preventie van ontstekingsgerelateerde aandoeningen.
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
DE60136706D1 (de) Ycin-acryloyl derivate und antimetabolische mitteln
EP1395227A4 (en) METHOD AND COMPOUNDS FOR DIAGNOSIS OF INFLAMMATORY DISEASES AND IDENTIFICATION OF PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal